Data of InnoCare's Orelabrutinib for the Treatment of MS Released at 2025 ACTRIMS Forum
InnoCare Pharma Announced today that the Phase II Results of Orelabrutinib for the Treatment of Relapsing-Remitting Multiple scler.
February 26, 2025
by PharmaSources
Scientists Discover How the 'Mono' Virus Might Trigger MS
A one-two punch from science has clearly tagged the mononucleosis virus, Epstein-Barr, as a major cause of multiple sclerosis.
January 26, 2022
by drugs.com
NEWS SEC-MS: a “powerful tool” for ADC analysis, find researchers
In a new study, scientists demonstrated that size exclusion chromatography (SEC) could be successfully combined with mass spectrometry (MS) to characterise antibody-drug conjugates (ADCs) on the intact molecular level.
October 28, 2021
by EuropeanPharmaceuticalReview
Biogen announces results from Phase IIIb NOVA study for MS
Results from the NOVA study show every six-week dosing with natalizumab is as effective as every four-week in relapsing-remitting MS.
August 6, 2021
by europeanpharmaceuticalreview
On World Brain Day Join WFN, MSIF to Stop Multiple Sclerosis
On July 22, the World Federation of Neurology (WFN) and MS International Federation (MSIF) are leading the global World Brain Day campaign to raise awareness for multiple sclerosis (MS).
July 20, 2021
by prnasia
First Signs of MS May Often Go Undiagnosed
Early symptoms of multiple sclerosis may commonly be missed for years before the right diagnosis is made, a new study suggests.
June 28, 2021
by drugs
Novartis reveals long-term results for MS therapy Kesimpta
Novartis has revealed new long-term data for its B-cell targeting therapy Kesimpta, showing that mean immunoglobulin G (IgG) and immunoglobulin M (IgM) were preserved in adults with relapsing multiple sclerosis (MS) receiving the therapy over 3.5 years.
June 24, 2021
by pharmatimes
InFlectis BioScience Licenses Rights to a Potential New Class of Therapies for Demyelinating Diseases from The University of Chicago
InFlectis BioScience has been granted exclusive patent rights from the University of Chicago to use a family of small molecules for the treatment of demyelinating diseases.
June 23, 2021
by firstwordpharma
EC approves Ponvory for relapsing MS
The European Commission (EC) has cleared Janssen’s Ponvory for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease.
May 26, 2021
by pharmatimes
UK NICE rejects NHS use of ozanimod for MS treatment
The UK National Institute for Health and Care Excellence (NICE) has decided not to recommend ozanimod for the treatment of relapsing multiple sclerosis (MS) patients on National Health Service (NHS) in England and Wales.
May 17, 2021
by pharmaceutical-technology
UK launch for progressive multiple sclerosis mega-trial
The MS Society had announced that a world-first mega-trial for progressive multiple sclerosis (MS) will be launched in the UK later this year.
May 8, 2021
by pharmatimes
Novartis’ MS therapy Kesimpta wins NICE backing
Novartis’ Kesimpta has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of relapsing remitting multiple sclerosis (RRMS) in adult patients.
April 22, 2021
by pharmatimes